Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics.

Vessillier, Sandrine et al.·Annals of the rheumatic diseases·2012·
RPEP-020972012RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics.
Published In:
Annals of the rheumatic diseases, 71(1), 143-9 (2012)
Database ID:
RPEP-02097

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-02097·https://rethinkpeptides.com/research/RPEP-02097

APA

Vessillier, Sandrine; Adams, Gill; Montero-Melendez, Trinidad; Jones, Rita; Seed, Michael; Perretti, Mauro; Chernajovsky, Yuti. (2012). Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics.. Annals of the rheumatic diseases, 71(1), 143-9. https://doi.org/10.1136/annrheumdis-2011-200100

MLA

Vessillier, Sandrine, et al. "Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics.." Annals of the rheumatic diseases, 2012. https://doi.org/10.1136/annrheumdis-2011-200100

RethinkPeptides

RethinkPeptides Research Database. "Molecular engineering of short half-life small peptides (VIP..." RPEP-02097. Retrieved from https://rethinkpeptides.com/research/vessillier-2012-molecular-engineering-of-short

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.